<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01032486</url>
  </required_header>
  <id_info>
    <org_study_id>TNC-RAS-PD/01</org_study_id>
    <secondary_id>REST</secondary_id>
    <nct_id>NCT01032486</nct_id>
  </id_info>
  <brief_title>Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease</brief_title>
  <acronym>PD</acronym>
  <official_title>An Open-Label, Multi-Center, Single Arm Study to Evaluate the Effects of Azilect® on Sleep Disturbances in Parkinson's Disease Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceutical Industries</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the effect of Azilect® on sleep disturbances
      in Parkinson's Disease patients, after 2 months of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to end of the study in sleep disturbances as measured with the Parkinson's Disease Sleep Scale (PDSS).</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to end of the study in daytime sleepiness as measured with the Epworth Sleepiness Scale (ESS).</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">120</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Azilect</arm_group_label>
    <description>Subjects with a diagnosis of idiopathic Parkinson's disease eligible to Azilect® treatment based on the investigator's clinical assessment and according to the Canadian product monograph.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rasagiline mesylate</intervention_name>
    <description>Azilect® tablets (0.5mg or 1.0 mg) administered orally once daily</description>
    <arm_group_label>Azilect</arm_group_label>
    <other_name>Rasagiline mesylate, Azilect</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This is a sample of participants with Parkinson's disease who will be prescribed Azilect®
        treatment as per Canadian product monograph in order to observe changes in sleep behaviour.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  idiopathic Parkinson's disease.

          -  eligible to Azilect® treatment as per Canadian product monograph

        Exclusion Criteria:

          -  exclusion (e.g. drug-drug interactions, contraindications, warnings and precautions)
             based on the Canadian product monograph.

          -  investigational drug within 30 days prior to study

          -  use of Azilect® or selegiline within 60 days prior to study

          -  significant medical condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel Panisset, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>André Barbeau Movement Disorders Unit, Centre Hospitalier Université de Montréal (CHUM)</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2009</study_first_submitted>
  <study_first_submitted_qc>December 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2009</study_first_posted>
  <last_update_submitted>August 27, 2013</last_update_submitted>
  <last_update_submitted_qc>August 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rasagiline</keyword>
  <keyword>Sleep</keyword>
  <keyword>Sleepiness</keyword>
  <keyword>Parkinson's Disease Sleep Scale</keyword>
  <keyword>Epworth Sleepiness Scale</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rasagiline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

